It is widely accepted that the development of advanced non‐small cell lung cancer (NSCLC) relies on gene mutations and some of them act as drivers of neoplastic transformation.[1, 2, 3, 4] Patients with mutations of epidermal growth factor receptor (EGFR) and translocations of anaplastic lymphoma kinase (ALK) can be treated with tyrosine kinase inhibitor (TKI)‐based target therapy whose efficacy has been fully demonstrated and many guidelines suggest the TKIs are the first line treatment for these patients.[5, 6, 7]. This evidence concerns the gene ALK and non-small cell lung carcinoma.